Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Hangzhou Qihan Biotech Co., Ltd.

News headline image
Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T Therapy for Refractory Systemic Lupus Erythematosus
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Presents New Clinical Data on Allogeneic CAR-T Cell Therapies and Preclinical Data on In Vivo CAR-T at the American Society of Hematology (ASH) Annual Meeting
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Announces Multiple Presentations at the 2025 American Society of Hematology (ASH) Annual Meeting
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Announces FDA Clearance of IND for QT-019B, a Universal Dual-Target CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
iPSC-CAR-NK Cell Therapy Clinical Result Published in Cell, Marking a Global Breakthrough in Autoimmune Disease Treatment
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Presented its Breakthrough CAR-T Research at ASGCT 2025
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Announces Appointment of Carl June to Scientific Advisory Board
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Announces Publication in Microbiology Spectrum on CRISPR-Cas Multiplexed Genome Editing for Reducing African Swine Fever Virus
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Appoints Yingyong Xu as its Chief Medical Officer
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Appoints Naxin Yao to its Board of Directors
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
News headline image
Qihan Biotech Appoints Tony W. Ho to its Board of Directors
From Hangzhou Qihan Biotech Co., Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.